Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
3079 Comments
1785 Likes
1
Arye
Loyal User
2 hours ago
Real-time US stock market capitalization analysis and size classification for appropriate risk assessment. We help you understand how company size impacts volatility and expected returns in different market conditions.
π 198
Reply
2
Tiofilo
Power User
5 hours ago
I wish someone had sent this to me sooner.
π 28
Reply
3
Olas
Daily Reader
1 day ago
This feels like step 7 but I missed 1-6.
π 160
Reply
4
Jomara
Community Member
1 day ago
Ah, what a missed chance! π©
π 273
Reply
5
Idika
Influential Reader
2 days ago
I donβt get it, but I trust it.
π 120
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.